Ellie Kincaid

Researcher attacks journal for retracting his paper on COVID-19 drug

A journal has retracted a paper reporting the results of a clinical trial in which a drug cut COVID-19 hospitalization for men by 90%.

The research group’s other work has attracted a lot of attention in Brazil – including praise from president Jair Bolsonaro and criticism from research regulators – for their dramatic results. In a Twitter thread, one of the authors claimed, without evidence, that the journal “may have received bribery to persecute us and retract our study.”

The article, “Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial,” was published in Frontiers in Medicine last July and has been cited 15 times, according to Clarivate’s Web of Science.

The study quickly attracted criticism, according to the retraction notice:

Medical school dean up to five retractions

A kidney research group led by a medical school dean has accumulated five retractions.

All five came within the last year, after commenters on PubPeer pointed out image similarities.

Joseph I. Shapiro, vice president and dean of the Joan C. Edwards School of Medicine of Marshall University in Huntington, West Virginia, is an author on each of the five papers and corresponding author for two. (Shapiro recently said he will be stepping down at the end of this month after ten years as dean, but will remain a tenured professor, according to a news report.)

A paper claimed to describe ‘the first potent and specific anti-COVID-19 drug.’ Now it’s retracted.

A paper about the discovery of “the first potent and specific anti-COVID-19 drug” has been retracted after it emerged that the compound wasn’t so novel after all.

The article, published in May 2021 in Chemical Papers has been cited seven times, according to Clarivate Analytics’ Web of Science.

As the paper’s sole author, Amgad M. Rabie, writes in the abstract:

A stolen manuscript, part two: The plagiarist begs for forgiveness as another group plagiarizes the same work

In 2019, we wrote about a reviewer who stole a manuscript and published it under his own name. Today, we bring you the sequel.

The sequel involves a plea for forgiveness after the plagiarized paper was retracted, and a second allegation of stealing work – which has prompted the target of the plagiarism to wonder if a more serious response from the journal to the first instance would have discouraged the second.

We obtained an email the reviewer, Yuvarajan Devarajan, sent after the retraction to Mina Mehregan, a mechanical engineer at Ferdowsi University of Mashhad in Iran whose work he copied. In it, he explains what happened, and asks, beginning in all caps in the subject line, for her to “FORGIVE ME IF POSSIBLE”:

Former Weill Cornell cancer researcher up to 20 retractions; investigation’s findings are with Feds

The journal Cancer Prevention Research has retracted nine papers at once from a group of cancer researchers led by Andrew Dannenberg, formerly of Weill Cornell Medicine.

The bundle of retractions brings Dannenberg’s total to 20, according to our database, nearly doubling the 11 he had previously. Kotha Subbaramaiah, also formerly of Weill Cornell Medicine, is a coauthor on all of the newly retracted papers, and two of the notices point the finger at figures that he prepared.

Dannenberg and Subbaramaiah retired from Cornell in the space of three months in late 2020 and early 2021, Retraction Watch has learned, and the university has forwarded a report of their investigation into the matter to the U.S. Office of Research Integrity.

Urology researcher under investigation for double-dipping has another paper retracted

A urology researcher who stepped down from his post as department chair after an institutional investigation prompted by Retraction Watch reporting has lost another paper.

The article apparently was not flagged during a misconduct investigation, but a PubPeer commenter noted overlapping images in August 2021.

Hari Koul had been interim chair of the department of biochemistry and molecular biology at LSU Health New Orleans until last December. He stepped down from the post (but remains a professor) amid the university’s investigation of allegations that he secured grants from two federal agencies for the same research project, following reporting by Retraction Watch in October.

An LSU Health New Orleans spokesperson told Retraction Watch the “process has not been completed.”

Cornell food marketing researcher who retired after misconduct finding is publishing again

Brian Wansink, the food marketing researcher who retired from Cornell in 2019 after the university found that he had committed academic misconduct, has published two new papers.

The articles, in Cureus and the International Journal of Community Medicine and Public Health, appear to use data that are at least a decade old. Wansink’s only coauthor on the papers is Audrey Wansink, a high school student and, evidently, his daughter. Brian Wansink did not respond to Retraction Watch’s request for comment.

Wansink’s work came under scrutiny beginning in 2016, after he published a blog post that described research practices that sounded like p-hacking to some readers. Other researchers started reviewing his published papers and found many issues.

‘Inadvertently published’ paper by pharma employee retracted almost a year later

A Takeda employee has lost a 2021 paper that the journal says it “inadvertently published.”

The article, “Seasonal and Secular Periodicities Identified in the Dynamics of US FDA Medical Devices (1976–2020): Portends Intrinsic Industrial Transformation and Independence of Certain Crises,” appeared in Therapeutic Innovation & Regulatory Science. It has yet to be cited, according to Clarivate Analytics’ Web of Science

The retraction notice from a few days ago says, in full:

The “internet may be a challenging venue”: Biomedical engineering group up to four retractions

A group of biomedical engineering researchers has lost four papers because they appear to be recycling their images from other papers.

The retractions for the group, from Banaras Hindu University in India, span papers published between 2011 and 2014. The retractions began in 2020, after anonymous PubPeer commenters pointed out the similarities between images. The four papers have been cited a total of 140 times, according to Clarivate Analytics’ Web of Science.

The latest paper to be retracted, “Alleviation of glutamate-mediated neuronal insult by piroxicam in rodent model of focal cerebral ischemia: a possible mechanism of GABA agonism,” was originally published in Springer Nature’s Journal of Physiology and Biochemistry in 2014. It has been cited 12 times.

According to the retraction notice:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: